While the MedicalXpress summary accurately reports Lund University’s development of genetic risk scores (GRS) from GWAS data to predict both diabetes onset and coronary artery disease (CAD), it stops short of exploring the transformative potential for precision medicine and overlooks critical context from prior research. The study, an observational cohort analysis published in Diabetes Care (2026, DOI: 10.2337/dc25-1711), leveraged the Malmö Diet and Cancer (MDC) population-based cohort of 24,025 participants (4,105 incident diabetes cases over long-term follow-up) to demonstrate that a GRS for the mild obesity-related diabetes (MOD) subgroup robustly predicted CAD even prior to diabetes diagnosis. No conflicts of interest were reported; however, as with most GWAS-derived scores, the work is limited by predominant European ancestry, reducing immediate generalizability.

This builds directly on the foundational 2018 observational study by Ahlqvist et al. (The Lancet Diabetes & Endocrinology, n≈8,500 from the ANDIS registry), which used data-driven clustering on six clinical variables to define five reproducible diabetes subgroups, including MOD—characterized by early-onset, obesity-driven insulin resistance. What mainstream coverage consistently misses is the mechanistic pattern connecting MOD to accelerated atherosclerosis: chronic low-grade inflammation and ectopic fat deposition appear to amplify CAD risk beyond what traditional risk calculators capture. A 2022 synthesis in Nature Reviews Endocrinology (Prasad & Groop) on precision diabetes further supports this by highlighting how subgroup-specific trajectories reveal heterogeneous complication risks that generic type 2 diabetes prevention trials (such as the Diabetes Prevention Program and its observational extensions) largely failed to address, showing only modest long-term cardiovascular benefits across broad populations.

The Lund team’s finding that DNA-based MOD GRS predicts CAD decades earlier aligns with emerging UK Biobank analyses (e.g., 2023 observational data linking obesity-related polygenic scores to premature coronary events). This identifies a actionable window for targeted interventions—such as early GLP-1 receptor agonists or SGLT2 inhibitors, which have shown superior cardiovascular outcomes in obesity-dominant phenotypes in RCTs like SELECT and EMPA-REG. Conventional coverage often treats diabetes as monolithic, ignoring how precision tools like these GRS could stratify patients in their 30s or 40s for intensive lifestyle, pharmacologic, or monitoring protocols, potentially reducing the 70-80% lifetime CAD risk that remains the leading cause of death in diabetes. Future mechanistic studies announced by the team on MOD-specific pathways (inflammation, endothelial dysfunction) could further close the gap between genetic prediction and therapy. Ultimately, this work signals a shift from reactive complication management to proactive, genetically informed prevention—addressing a blind spot that has persisted across decades of diabetes research.